Home
-
DCAT Week in Review: A Snapshot View of DCAT’s Education Programs
The education programs at DCAT Week 2026, held March 23–26, in New York, featured senior executives and thought leaders providing perspectives on key issues impactful to the business of bio/pharma development and manufacturing and the pharma customer–supplier relationship.
-
Oral Obesity Drug Battle Is On with FDA OK for Lilly’s Orforglipron
Lilly is entering the oral obesity drug market by gaining FDA approval for Foundayo (orforglipron), a small-molecule (non-peptide) oral GLP-1 receptor agonist, setting up head-on competition with an oral version of Novo Nordisk’s obesity drug, Wegovy (semaglutide).
-
What is Top of the Industry’s Sustainability Agenda in 2026?
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.
DCAT MEMBER COMPANY COMMUNITY
-
New DCAT Member Company Alert
Welcome to the newest Member Companies in the Drug, Chemical & Associated Technologies Association (DCAT). DCAT is pleased to welcome the following companies to the DCAT Member Community. To view…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
New Episode: Production to Prescription Podcast: What Tops the Industry’s Sustainability Agenda for 2026?
As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology…
-
ESG Update: DCAT Member Companies in the Community
The latest ESG (environmental, social and governance)news from DCAT Member Companies on how they are making an impact globally and in their local communities. Have a ESG news announcement to share for…
